NASDAQ:UPB

Upstream Bio Q2 2026 Earnings Results & Report

Upstream Bio logo
$2.00 -0.08 (-3.85%)
Closing price 04:00 PM Eastern
Extended Trading
$2.02 +0.02 (+0.75%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Upstream Bio beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 11, 2026. The company reported EPS of -$0.73 versus the -$0.7444 consensus estimate, while revenue of $773 thousand topped the $561 thousand estimate by $212.00 thousand.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Upstream Bio EPS Results

Actual EPS
-$0.73
Consensus EPS
-$0.7444
Beat/Miss
Beat by +$0.0144
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Upstream Bio Revenue Results

Actual Revenue
$773 thousand
Expected Revenue
$561 thousand
Beat/Miss
Beat by +$212.00 thousand
YoY Revenue Growth
N/A

Upstream Bio Q2 2026 Earnings FAQ

Upstream Bio (NASDAQ:UPB) reported earnings of -$0.73 per share for Q2 2026, beating the consensus estimate of -$0.7444. The report was announced on Tuesday, August 11, 2026.

Upstream Bio reported revenue of $773 thousand for Q2 2026, against a consensus estimate of $561 thousand.

Upstream Bio Earnings Headlines

HC Wainwright Increases Earnings Estimates for Upstream Bio
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More Upstream Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email.

About Upstream Bio

Upstream Bio (NASDAQ:UPB) is a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases. The company is based in Waltham, Massachusetts, and its research focuses on pathways involved in immune and inflammatory responses.

Its lead product candidate, verekitug (UPB-101), is an antibody designed to block the receptor for thymic stromal lymphopoietin, a protein associated with inflammation. Upstream Bio is developing verekitug for conditions including asthma and chronic rhinosinusitis with nasal polyps.

The company’s work is focused on drug development and clinical research; it does not have a marketed product portfolio.

View Upstream Bio Profile